Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Conditions
Interventions
Nivolumab
Gemcitabine
+4 more
Locations
141
United States
Southern Cancer Center, Inc.
Mobile, Alabama, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Local Institution - 0034
Tucson, Arizona, United States
Local Institution - 0016
Stanford, California, United States
University Of Colorado Hosp
Aurora, Colorado, United States
Local Institution - 0020
New Haven, Connecticut, United States
Start Date
March 27, 2014
Primary Completion Date
July 1, 2016
Completion Date
May 27, 2022
Last Updated
March 2, 2023
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions